The fact that LEN-TACE showed good efficacy and safety in tumors that would not respond to TACE alone makes the TACTICS-L trial extremely significant.
← all excerpts
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
1
—
—